CKD-GADOLINIUM

From NeuroRehab.wiki

Revision as of 20:03, 13 March 2023 by Dr Appukutty Manickam (talk | contribs) (Imported from text file)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

SUMMARY

1. Avoid gadolinium contrast in patients with CKD stages 4 and 5.

2. Know that gadolinium can cause nephrogenic systemic fibrosis (NSF) in patients with advanced CKD.

3. NSF - presents as a thickening of the skin with erythema, symmetrical plaques, papules, or nodules. Usually it starts distally and moves proximally. Systemic symptoms: organ fibrosis, scleral yellowing, and tissue calcification.

4. Definitive diagnosis is made with deep punch biopsies of involved skin.

5. Course is progressive, sometimes fulminant. If renal recovery occurs, commonly the NSF remits, otherwise - no treatment.


Reference(s)

Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].